Here are the 424B prospectus supplements from Cyclerion Therapeutics, Inc. (CYCN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CYCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYCN filings page.
Cyclerion Therapeutics, Inc. plans to merge with Korsana Biosciences, Inc., issuing more than 20% of its existing common stock (plus Series B preferred) to Korsana securityholders as merger consideration, subject to shareholder approvals and other closing conditions. The combined company will be renamed Korsana Biosciences, Inc., with an operating subsidiary named Korsana Biosciences Operating Company, LLC, and is expected to trade on Nasdaq under the symbol “KRSA” after the merger.
Based on a June 30, 2026 capitalization snapshot and Cyclerion estimated net cash of $(2.5) million, each share of Korsana common and Series A preferred stock is estimated to receive about 1.4735 shares of Cyclerion common stock. On a fully diluted basis after the merger, existing Cyclerion securityholders are expected to own about 1.1% of the combined company and former Korsana securityholders about 98.9%, including roughly 53.4% tied to Korsana’s approximately $380.0 million pre-closing financing. Cyclerion shareholders will vote on multiple proposals, including Nasdaq stock issuance, an increase in authorized common shares from 400,000,000 to 700,000,000, a reverse stock split in a 1‑for‑2 to 1‑for‑10 range, and a redomestication to the Cayman Islands, several of which are conditions to completing the merger.